Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes
Primary Purpose
Diabetes, Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
biphasic insulin aspart
biphasic human insulin
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes for at least 24 months
- Insulin treatment for the pase 3 months
- HbA1c (glycosylated haemoglobin) below 13%
- BMI (Body Mass Index) below 40 kg/m^2
- Ability and willingness to perform self-blood glucose monitoring
Exclusion Criteria:
- Receipt of any investigational drug within 4 weeks prior to this trial
- Treatment of OHAs (Oral Hypoglycaemic Agents) within 4 weeks prior to this trial
- Total daily insulin dosage less than or equal to 1.8 IU/kg
Sites / Locations
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
A
B
Arm Description
Outcomes
Primary Outcome Measures
HbA1c (glycolated haemoglobin)
Secondary Outcome Measures
Prandial increment in blood glucose
7-point blood glucose profile
Number and severity of adverse events
Number and severity of local tolerability issues at the injection site
Number and severity of hypoglycaemic episodes
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01467401
Brief Title
Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes
Official Title
A Multi-National, Multi-Centre, Randomised, Open-Labelled, Parallel Trial Comparing Efficacy and Safety of NovoMix® 30 FlexPen® and Mixtard® 30 Twice Daily Injections in Subjects With Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
August 19, 2002 (Actual)
Primary Completion Date
May 15, 2003 (Actual)
Study Completion Date
May 15, 2003 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This trial is conducted in Europe. The aim of this trial is to investigate the efficacy and safety of biphasic insulin aspart (NovoMix®30) to that of biphasic human insulin (Mixtard® 30) in subjects with type 2 diabetes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
292 (Actual)
8. Arms, Groups, and Interventions
Arm Title
A
Arm Type
Experimental
Arm Title
B
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
biphasic insulin aspart
Intervention Description
Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
Intervention Type
Drug
Intervention Name(s)
biphasic human insulin
Intervention Description
Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
Primary Outcome Measure Information:
Title
HbA1c (glycolated haemoglobin)
Secondary Outcome Measure Information:
Title
Prandial increment in blood glucose
Title
7-point blood glucose profile
Title
Number and severity of adverse events
Title
Number and severity of local tolerability issues at the injection site
Title
Number and severity of hypoglycaemic episodes
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes for at least 24 months
Insulin treatment for the pase 3 months
HbA1c (glycosylated haemoglobin) below 13%
BMI (Body Mass Index) below 40 kg/m^2
Ability and willingness to perform self-blood glucose monitoring
Exclusion Criteria:
Receipt of any investigational drug within 4 weeks prior to this trial
Treatment of OHAs (Oral Hypoglycaemic Agents) within 4 weeks prior to this trial
Total daily insulin dosage less than or equal to 1.8 IU/kg
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Global Clinical Registry (GCR, 1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Esbjerg
ZIP/Postal Code
6700
Country
Denmark
Facility Name
Novo Nordisk Investigational Site
City
Herning
ZIP/Postal Code
7400
Country
Denmark
Facility Name
Novo Nordisk Investigational Site
City
Holbæk
ZIP/Postal Code
4300
Country
Denmark
Facility Name
Novo Nordisk Investigational Site
City
Næstved
ZIP/Postal Code
4700
Country
Denmark
Facility Name
Novo Nordisk Investigational Site
City
Randers
Country
Denmark
Facility Name
Novo Nordisk Investigational Site
City
Silkeborg
ZIP/Postal Code
8600
Country
Denmark
Facility Name
Novo Nordisk Investigational Site
City
Skive
ZIP/Postal Code
7800
Country
Denmark
Facility Name
Novo Nordisk Investigational Site
City
Viborg
Country
Denmark
Facility Name
Novo Nordisk Investigational Site
City
Århus C
ZIP/Postal Code
8000
Country
Denmark
Facility Name
Novo Nordisk Investigational Site
City
Bekkestua
ZIP/Postal Code
1357
Country
Norway
Facility Name
Novo Nordisk Investigational Site
City
Bergen
ZIP/Postal Code
NO-5012
Country
Norway
Facility Name
Novo Nordisk Investigational Site
City
Haugesund
Country
Norway
Facility Name
Novo Nordisk Investigational Site
City
Hønefoss
Country
Norway
Facility Name
Novo Nordisk Investigational Site
City
Moelv
Country
Norway
Facility Name
Novo Nordisk Investigational Site
City
Oslo
ZIP/Postal Code
0370
Country
Norway
Facility Name
Novo Nordisk Investigational Site
City
Tromsø
ZIP/Postal Code
9038
Country
Norway
Facility Name
Novo Nordisk Investigational Site
City
Vennesla
Country
Norway
Facility Name
Novo Nordisk Investigational Site
City
Åsgårdstrand
Country
Norway
Facility Name
Novo Nordisk Investigational Site
City
Arvika
ZIP/Postal Code
671 80
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Avesta
ZIP/Postal Code
774 82
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Bjuv
ZIP/Postal Code
267 38
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Broby
ZIP/Postal Code
280 60
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Färgelanda
ZIP/Postal Code
458 32
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Grästorp
ZIP/Postal Code
467 22
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Göteborg
ZIP/Postal Code
416 65
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Göteborg
ZIP/Postal Code
416 85
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Göteborg
ZIP/Postal Code
417 02
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Göteborg
ZIP/Postal Code
417 17
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Habo
ZIP/Postal Code
566 32
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Helsingborg
ZIP/Postal Code
254 57
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Härnösand
ZIP/Postal Code
871 82
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Hässleholm
ZIP/Postal Code
281 25
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Jönköping
ZIP/Postal Code
551 11
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Karlstad
ZIP/Postal Code
651 85
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Karlstad
ZIP/Postal Code
652 24
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Kristianstad
ZIP/Postal Code
291 38
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Kristinehamn
ZIP/Postal Code
681 80
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Kungsbacka
ZIP/Postal Code
434 80
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Malmö
ZIP/Postal Code
205 02
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Mellerud
ZIP/Postal Code
464 30
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Mölndal
ZIP/Postal Code
431 80
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Norrköping
ZIP/Postal Code
602 36
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Skövde
ZIP/Postal Code
541 85
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Stockholm
ZIP/Postal Code
116 91
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Säffle
ZIP/Postal Code
661 81
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Tomelilla
ZIP/Postal Code
273 34
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Torsby
ZIP/Postal Code
685 29
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Trollhättan
ZIP/Postal Code
461 40
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Trollhättan
ZIP/Postal Code
461 85
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Tyresö
ZIP/Postal Code
135 21
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Uddevalla
ZIP/Postal Code
451 80
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Värnamo
ZIP/Postal Code
331 85
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Örebro
ZIP/Postal Code
701 85
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Örebro
ZIP/Postal Code
702 15
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Örebro
ZIP/Postal Code
703 51
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Östersund
ZIP/Postal Code
831 62
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Östersund
ZIP/Postal Code
831 83
Country
Sweden
12. IPD Sharing Statement
Links:
URL
http://novonordisk-trials.com
Description
Clinical Trials at Novo Nordisk
Learn more about this trial
Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes
We'll reach out to this number within 24 hrs